Human immunoglobulin preparations for intravenous or subcutaneous administration are
the cornerstone of treatment in patients with primary immunodeficiency diseases affecting …

Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging
treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene …

The development and regulatory approval of chimeric antigen receptor T cell (CAR-T)
therapies targeting the B-lineage surface antigen CD19 represents a major milestone in …

Primary immunodeficiency disease (PIDD) associated with hypogammaglobulinemia is
typically treated with immunoglobulin replacement therapy. When administered as …

BACKGROUND: Common variable immunodeficiency disorders (CVIDs) are the most
common forms of symptomatic primary antibody failure in adults and children. Replacement …

A 5-years multicenter prospective study on 201 patients with common variable
immunodeficiencies and 101 patients with X-linked agammaglobulinemia over a cumulative …

Primary antibody deficiencies require lifelong replacement therapy with immunoglobulin (Ig)
G to reduce the incidence and severity of infections. Both subcutaneous and intravenous …

T cell engagers (TCE) such as chimeric antigen receptor (CAR) T cell therapy and bispecific
antibodies (BiAbs) for the treatment of multiple myeloma (MM) have significantly improved …

Chimeric antigen receptor (CAR) T-cell therapy is a dynamic therapy of engineered T cells
targeting neoplastic cells, which offers impressive long-term remissions for aggressive …

Infection claims the lives of approximately 3000 neonates worldwide every day. 1 Preterm
newborns are the most affected because they exhibit the highest sepsisrelated morbidity …